The company said total revenue for Q1 2025 rose 9% year over year to $8.1 billion. Product sales grew 11%. The company cited 14% volume growth, partially offset by 6% lower net selling price.

1. 01

   The company said total revenue for Q1 2025 rose 9% year over year to $8.1 billion. Product sales grew 11%. The company cited 14% volume growth, partially offset by 6% lower net selling price.

2. 02

   Amgen said GAAP earnings per share for Q1 were $3.20, compared with a GAAP loss per share of $0.21 a year earlier. The company cited an unrealized gain on its BeiGene equity investment, which was partly offset by an Otezla intangible asset impairment charge of $800 million.

3. 03

   The company said non-GAAP earnings per share for Q1 increased 24% from $3.96 to $4.90. Non-GAAP operating income rose from $3.1 billion to $3.6 billion, and non-GAAP operating margin increased 2.5 percentage points to 45.7%.

4. 04

   The company said free cash flow for Q1 was $1.0 billion, compared with $0.5 billion a year earlier, and that it reduced principal debt outstanding by $2.8 billion. The company also presented its full-year 2025 total revenue outlook of $34.3 billion to $35.7 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.